HC Wainwright Issues Optimistic Forecast for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities researchers at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a report released on Wednesday, April 2nd. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.45) per share for the quarter, up from their previous estimate of ($0.46). HC Wainwright currently has a "Buy" rating and a $500.00 target price on the stock. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals' Q4 2025 earnings at $1.38 EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at $12.37 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

A number of other research analysts have also issued reports on ALNY. Royal Bank of Canada boosted their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Stifel Nicolaus boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. Finally, Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $11.49 on Monday, hitting $237.77. 1,577,336 shares of the company traded hands, compared to its average volume of 863,403. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a 50 day moving average of $253.20 and a 200-day moving average of $258.37. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $30.93 billion, a PE ratio of -109.57 and a beta of 0.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Whipplewood Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares during the last quarter. Larson Financial Group LLC raised its holdings in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $33,000. Finally, Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $35,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.